The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

Pfizer (NYSE: PFE) posted adjusted earnings per share of $0.63 for Q4, exceeding the analyst consensus of $0.48. Revenue came ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...